ADMA Biologics

Recent news

• Rating change
  Cantor Fitzgerald Downgrades ADMA Biologics(ADMA.US) to Hold Rating, Maintains Target Price $30
  Market Newswire · 2026/3/26
• Company notice
  ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.
  SEC · 2026/3/11
• Rating change
  Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $30
  Market Newswire · 2026/2/26
• Rating change
  Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $35
  Market Newswire · 2025/5/9
• Rating change
  Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $32
  Market Newswire · 2025/8/18
• Company notice
  ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.
  SEC · 2026/4/4
• Rating change
  Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $21
  Market Newswire · 2026/4/21
• Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $17
  Market Newswire · 2026/7/15
• Company notice
  ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.
  SEC · 2026/2/24
• Rating change
  Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $24
  Market Newswire · 2026/4/14
• Company notice
  4: ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.
  SEC · 2026/7/29
• Rating change
  Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $20
  Market Newswire · 2026/5/7
• CCORF Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $18
  Market Newswire · 2026/8/6
• Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Hold Rating, Cuts Target Price to $12
  Market Newswire · 2026/8/6
• Company notice
  ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Director Guiheen Lawrence P.
  SEC · 2026/3/18
• ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate
  Benzinga · 2026/8/6
• Rating change
  Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $32
  Market Newswire · 2025/5/9
• Raymond James Initiates ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $21
  Market Newswire · 2026/6/10
• Rating change
  CCORF Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $21
  Market Newswire · 2026/5/5
• Rating change
  Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $30
  Market Newswire · 2025/11/6

Headlines are aggregated automatically and are not independently verified or edited by our team.